Literature DB >> 9881958

Tumor necrosis factor is delivered to mitochondria where a tumor necrosis factor-binding protein is localized.

E C Ledgerwood1, J B Prins, N A Bright, D R Johnson, K Wolfreys, J S Pober, S O'Rahilly, J R Bradley.   

Abstract

The roles of the known tumor necrosis factor (TNF) receptors (TNFR-I and TNFR-II) and their associated signaling pathways in mediating the diverse actions of TNF remain incompletely defined. We have found that a proportion of exogenous TNF is delivered to mitochondria as well as to lysosomes. Using confocal and immunoelectron microscopy and Western blotting of subcellular fractions, we have identified a 60-kd protein in the inner mitochondrial membrane that is recognized by a monoclonal antibody to TNFR-II. In isolated mitochondria, this protein binds [125I]-TNF. This provides evidence of a mitochondrial binding protein for an extracellular ligand and demonstrates the presence of a pathway capable of delivering TNF from the cell surface to mitochondria. These findings suggest that TNF effects on cells may be due in part to a direct effect on mitochondria.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9881958

Source DB:  PubMed          Journal:  Lab Invest        ISSN: 0023-6837            Impact factor:   5.662


  14 in total

Review 1.  Immunobiology of human vascular endothelium.

Authors:  J S Pober
Journal:  Immunol Res       Date:  1999       Impact factor: 2.829

2.  Impaired redox status and cytochrome c oxidase deficiency in patients with polymyalgia rheumatica.

Authors:  P Chariot; X Chevalier; M Yerroum; I Drogou; F J Authier; R Gherardi
Journal:  Ann Rheum Dis       Date:  2001-11       Impact factor: 19.103

3.  TNFα protects cardiac mitochondria independently of its cell surface receptors.

Authors:  Lydia Lacerda; Joy McCarthy; Shazia F K Mungly; Edward G Lynn; Michael N Sack; Lionel H Opie; Sandrine Lecour
Journal:  Basic Res Cardiol       Date:  2010-08-01       Impact factor: 17.165

4.  Caveolae participate in tumor necrosis factor receptor 1 signaling and internalization in a human endothelial cell line.

Authors:  Alessio D'Alessio; Rafia S Al-Lamki; John R Bradley; Jordan S Pober
Journal:  Am J Pathol       Date:  2005-04       Impact factor: 4.307

5.  Type II tumour necrosis factor-alpha receptor (TNFR2) activates c-Jun N-terminal kinase (JNK) but not mitogen-activated protein kinase (MAPK) or p38 MAPK pathways.

Authors:  O J Jupp; S M McFarlane; H M Anderson; A F Littlejohn; A A Mohamed; R H MacKay; P Vandenabeele; D J MacEwan
Journal:  Biochem J       Date:  2001-11-01       Impact factor: 3.857

6.  Targeting of tumor necrosis factor receptor 1 to low density plasma membrane domains in human endothelial cells.

Authors:  Alessio D'Alessio; Martin S Kluger; Jie H Li; Rafia Al-Lamki; John R Bradley; Jordan S Pober
Journal:  J Biol Chem       Date:  2010-05-28       Impact factor: 5.157

7.  TNFalpha trafficking in cerebral vascular endothelial cells.

Authors:  Weihong Pan; Abba J Kastin; Jeremy Daniel; Chuanhui Yu; Larisa M Baryshnikova; Christopher S von Bartheld
Journal:  J Neuroimmunol       Date:  2007-02-20       Impact factor: 3.478

8.  TNF-alpha-induced mitochondrial alterations in human T cells requires FADD and caspase-8 activation but not RIP and caspase-3 activation.

Authors:  Mehdi Shakibaei; Bokyung Sung; Gautam Sethi; Bharat B Aggarwal
Journal:  Antioxid Redox Signal       Date:  2010-09-15       Impact factor: 8.401

9.  Tumor necrosis factor alpha inhibits oxidative phosphorylation through tyrosine phosphorylation at subunit I of cytochrome c oxidase.

Authors:  Lobelia Samavati; Icksoo Lee; Isabella Mathes; Friedrich Lottspeich; Maik Hüttemann
Journal:  J Biol Chem       Date:  2008-06-05       Impact factor: 5.157

10.  TNFR1/phox interaction and TNFR1 mitochondrial translocation Thwart silica-induced pulmonary fibrosis.

Authors:  Fabrizio Fazzi; Joel Njah; Michelangelo Di Giuseppe; Daniel E Winnica; Kristina Go; Ernest Sala; Claudette M St Croix; Simon C Watkins; Vladimir A Tyurin; Donald G Phinney; Cheryl L Fattman; George D Leikauf; Valerian E Kagan; Luis A Ortiz
Journal:  J Immunol       Date:  2014-03-12       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.